Day: October 21, 2024

Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast’s interim financial results for FY 2023/24 the company will host a conference call to present the financial results and answer questions from investors and financial analysts.A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.Please note that the webcast of the conference call will be available during and after the event. Coloplast will be represented by:Kristian Villumsen – President & CEOAnders Lonning-Skovgaard – Executive Vice President, CFOAleksandra Dimovska – Vice President, Investor RelationsKristine Husted Munk – Senior Manager, Investor Relations  WebcastAny participants who do not wish to actively participate in the question & answer session,...

— IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 — BOSTON and ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the closing of a private placement of approximately $110 Million from the issuance and sale of shares of the Company’s common stock and accompanying warrants with potential aggregate financing of up to approximately $275 Million upon the full cash exercise of the warrants issued in...

Business Transformation Office Driving Strategic Initiatives to Accelerate Profitable Growth, Increase Margins and Drive Consistent Returns on Invested Capital in the Mid-to-High Teens Ad Hoc Transformation Committee of the Board to Oversee Execution of Strategic Initiatives Board of Directors Initiates Search for New Chief Financial Officer to Support the Achievement of the Company’s ROIC Goals Sheila Anderson Named to Newly Created Role of Chief Data and Analytics Officer to Lead Digital Transformation BROOKINGS, S.D., Oct. 21, 2024 (GLOBE NEWSWIRE) — Daktronics Inc (“Daktronics” or the “Company”) (Nasdaq – DAKT) today announced the next phase of its ongoing business transformation plan to accelerate profitable growth, increase profit margins, and drive returns that are consistently in the mid-to-high teens and well above...

The collaboration enables SoC designers to reduce project risk and integrate Arteris Ncore cache coherent interconnect IP and SiFive P870-D processors in large, high-performance applications CAMPBELL, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP which accelerates system-on-chip (SoC) creation, and SiFive, Inc., the gold standard for RISC-V computing, today announced the availability of the pre-verified solution to enable the development of high-performance applications in the datacenter market without the risk. The combination of the SiFive P870-D CPU and Arteris Ncore cache coherent interconnect IP accelerates the path for SoC design engineers to address the demanding AI workload requirements of the datacenter and embedded systems markets. SiFive’s P870-D CPU enables high...

PALO ALTO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) — Intapp, Inc., (Nasdaq: INTA), a leading global provider of AI-powered solutions for professionals at advisory, capital markets, and legal firms, will report fiscal first quarter 2025 financial results after the market close on November 4, 2024. On that day, management will host a webcast at 5 p.m. ET to discuss the company’s business and financial results. Investors and other interested parties can access the webcast as follows: What: Intapp fiscal first quarter 2025 financial results earnings webcast When: Monday, November 4, 2024 Time: 5 p.m. ET Live webcast: Investors | Intapp, Inc. Replay: An archived webcast of the event will be accessible from the “news and events” section of the company’s investor relations website at Investors | Intapp, Inc. The replay will be available...

·       Company introduces a top-tier team of chemists to lead innovation in hydrophilic coatings and develop cutting-edge, environmentally friendly solutions ·       Restructured R&D division, under new leadership, aims to enhance product offerings, improve operational efficiency, and drive future growth CONCORD, N.C. , Oct. 21, 2024 (GLOBE NEWSWIRE) — Hydromer, Inc. (OTC: HYDI), a leader in hydrophilic coating technologies for medical and industrial applications for over 44 years, is excited to announce the formation of a new Research and Development (R&D) division. This restructuring introduces a world-class science team focused on innovation and performance, adding two Ph.D. chemists and one M.S. chemist. Leading the team is Dr. Yonghua Zhou, Ph.D. in Polymer Science from the University of Massachusetts at Lowell....

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) — Endeavor Bancorp (OTCQX: EDVR) (the “Company,” or “Bancorp”), the holding company for Endeavor Bank (the “Bank”), today reported net income of $924,000, or $0.22 per diluted share, for the third quarter of 2024, compared to net income of $760,000, or $0.18 per diluted share, for the second quarter of 2024, and $1,218,000, or $0.29 per diluted share, for the third quarter of 2023. Pretax net income was $1.3 million in the third quarter compared to $1.1 million in the preceding quarter and $1.7 million in the third quarter of 2023. All financial results are unaudited. Results for the third quarter of 2024 included a $609,000 provision for credit losses, compared to a $451,000 provision for credit losses in the second quarter of 2024, and a $301,000 provision for credit losses in the third...

Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides the following corporate update to stockholders from Interim CEO Chris Ehrlich. To our Valued Stockholders: Following the events of the last several months, I believe it appropriate to discuss our recent progress and illuminate the path forward for CERo. As you know, we received notice of a clinical hold for CERO-1236 earlier this year. Since then, we have been diligently working to complete the experimental studies necessary to address and resolve the U.S. Food and Drug Administration’s...

New Trading Symbol “NAYA” Effective Tuesday October 22, 2024 SARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) — INVO Biosciences (Nasdaq: INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and autoimmune diseases through the merger of INVO Biosciences and NAYA Biosciences, today confirmed it has changed its corporate name to NAYA Biosciences Inc. and will begin trading under the new symbol “NAYA” at the market open on Tuesday, October 22, 2024. The CUSIP number for the Company’s common stock will remain unchanged. The name and symbol change follows the Company’s recent announcement on October 14th regarding the completion of its merger with NAYA Biosciences. The newly combined company will continue to operate the revenue-generating fertility business...

BISHOP, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) — North Bay Resources Inc. (the “Company” or “North Bay”) (OTC: NBRI) is pleased to announce the United States Department of Labor, Mining Safety and Health Administration (“MSHA”) for the Western District has issued all necessary approvals for the commencement of full-scale production at the Company’s Mt. Vernon Gold Mine located in Sierra County, California. The Company has received specific notices as follows:The application for Alternative Mine Rescue Capability for small and remote mines dated 10/11/2024 has been reviewed for compliance with the provisions of CFR 49.3 is approved;The Ventilation Plan dated 10/11/2024 has been received and reviewed for compliance with 30 CFR §57.8520—Ventilation Plan: no deficiencies noted;The Escape and Evacuation Plan for the Mt....